By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Rescuers attempt to dig free whale stranded on Germany's Baltic coast - 2Step by step instructions to Protect Your Retirement with Senior Protection.
- 3At least 7 dead as Israel renews attacks on Beirut and across Lebanon
- 4Foot fossil discovery could reshape human evolutionary history
- 5Parents search for children missing since a volcanic eruption in Colombia 40 years ago
- Bayer sues COVID vaccine makers over mRNA technology
- Figure out how to Detect the Best Rooftop Substitution Choices
- 6 Hints to Upgrade Your Charm, In addition to Your Mentality
- NASA set for first crewed moon return in over half a century
- Benihana is 60 years old. Gen Z is lining up.
- EPA watchdog finds nation’s most contaminated sites are vulnerable to flooding, wildfires
- More than 3 million eye drops have been recalled from CVS, Walgreens and other national retailers. How to check if yours are safe
- US FDA panel to weigh bid to market nicotine pouches as lower-risk than cigarettes
- Mars orbiter sees 'butterfly' crater spread its wings on the Red Planet
